CD46-targeted radiation antibody treatment for prostate cancer
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy
Researchers are improving a CD46-targeted radioactive antibody to better kill prostate cancer cells while sparing healthy tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11306690 on NIH RePORTER |
What this research studies
This project is developing a new antibody that delivers radiation directly to prostate cancer cells that have the CD46 marker. Scientists will attach the radioactive element actinium‑225 to the antibody using new chemical linkers to increase delivery to tumors. They will test these agents in advanced metastatic prostate cancer models and measure tumor response and side effects using tissue studies, metabolic profiling, and microscale radiation dose mapping. The team aims to find formulations that control cancer spread with lower damage to normal organs.
Who could benefit from this research
Good fit: Patients with advanced or metastatic prostate cancer that expresses the CD46 marker would be the most likely candidates for future clinical trials based on this work.
Not a fit: Patients whose tumors do not express CD46 or those with early-stage disease unlikely to need radioligand therapy may not benefit from this approach.
Why it matters
Potential benefit: If successful, this could become a more effective targeted treatment for advanced prostate cancer with fewer off‑target side effects.
How similar studies have performed: Other radioligand therapies for prostate cancer (for example PSMA-targeted agents) have shown clinical benefit, but CD46-directed radioimmunotherapy is a newer, less-tested approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Flavell, Robert Richard — University of California, San Francisco
- Study coordinator: Flavell, Robert Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.